Biogen Message Board - Msg: 8094289

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen

BIIB 182.09

+0.1%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Harold Engstrom who wrote (881)	3/1/1999 3:49:00 PM
From: Beltropolis Boy	of 1686

for what it's worth, an update on serono ... ----- Ares-Serono Expects News on Bid to Challenge Biogen MS Drug Norwell, Massachusetts, Feb. 25 (Bloomberg) -- Ares-Serono SA, the world's No. 1 fertility-drug maker, expects to learn within coming days how regulators ruled on its application to sell the multiple sclerosis treatment Rebif in the U.S. The decision won't be as straightforward as a typical ruling on a new drug. Even if Rebif is approved, Serono must clear a second hurdle as it seeks to challenge Biogen Inc. for control of an MS drug market expected to reach $1 billion a year. Serono can't sell the drug in the U.S. until 2003 unless the Food and Drug Administration agrees to override rulings that gave exclusive marketing rights to two MS treatments similar to Rebif.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next